Literature DB >> 6085363

Antihypertensive effects on blood pressure at rest and during exercise of calcium antagonists, beta-receptor blockers, and their combination in hypertensive patients.

I W Franz, D Wiewel.   

Abstract

The efficacy of nifedipine (40 mg), nitrendipine (20 mg), and acebutolol (400 mg) in reducing blood pressure at rest and during exercise was assessed in 35 hypertensive patients using a crossover study with 4-week treatment periods. In 20 patients, the antihypertensive effect of the combination of nifedipine and acebutolol was investigated. Both the calcium antagonists nitrendipine and nifedipine and the beta-receptor blocker acebutolol led to a significant (p less than 0.001) and almost identical reduction in systolic and diastolic blood pressures at rest. This was also the case with the diastolic blood pressure during and after work. Both calcium antagonists also revealed a significant (p less than 0.01; p less than 0.001) reduction in systolic exercise blood pressure; however, this effect was more pronounced with acebutolol. The additional use of nifedipine significantly enhanced the antihypertensive effect of acebutolol under resting conditions (p less than 0.05) but particularly during (p less than 0.01) and after (p less than 0.001) exercise. No adverse reactions to the monotherapy or to the nifedipine and acebutolol combination were found, in particular no effect on the PQ interval or the serum lipids. It is concluded that nifedipine and nitrendipine and their combination with beta-blockers appear to offer an alternative therapeutic approach in the management of arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6085363

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

2.  Regression of left ventricular hypertrophy by acebutolol and nifedipine.

Authors:  I W Franz; U Tönnesmann; U Behr; R Ketelhut
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 3.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

4.  Effect of calcium channel blockade and beta-adrenoceptor blockade on short graded and single-level endurance exercises in normal men.

Authors:  L Vanhees; R Fagard; A Amery
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1988

5.  Regression of left ventricular hypertrophy during combined atenolol and nifedipine treatment.

Authors:  I W Franz; U Tönnesmann; U Behr; R Ketelhut
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

7.  Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy.

Authors:  M R Lawrence; F Broughton Pipkin
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 8.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

Review 9.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

10.  Addition of chlorthalidone to slow-release nifedipine in the treatment of arterial hypertension: a controlled study versus placebo.

Authors:  L A Ferrara; T Marotta; F Pasanisi; P Mastranzo; M Mancini
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.